Healthcare facilities were forced outside hospital boundaries during the pandemic, as Covid-19 pushes the healthcare industries in an entirely new way. This pandemic leads health care to a rise in home diagnostics.
The home testing facility became prominent and people tried to avoid hospital-based laboratories. Covid 19 shifts our lifestyle to home confinement which has led us to a strong inclination toward home health check-ups.
The pandemic has caused numerous health issues like damaged lungs, cardiovascular problems, high blood pressure and Type 2 Diabetes, are affecting people’s lives negatively
These health issues have drived a significant shift toward the diagnosis managment. From collecting blood samples at home to providing consultation through phone, the healthcare ecosystem is gradually turning out to be more home-friendly.
Additionally, the convenience factor that sets in as the ease of doing health checks is its availability at one’s doorstep. Earlier, patients had to walk into the lab to get tests done. Over the past five years, we are seeing a huge change in preference toward home blood collections.
Path Lab chains has witnessed a tremendous growth in home blood collections and this trend is likely to increase in upcoming time.
Telepsychology, whether through phone, webcam, email, or text messaging, has been around for more than 20 years and is most commonly utilised by military personnel. However, as the number of smartphone users grows, app-based businesses will be able to provide more accessible and affordable therapy.
Despite the growing acceptance of digital therapeutics (DTx) and digital care technologies, payment will remain a challenge in 2022. With nearly 1,500 research released in the last five years, the entire body of clinical evidence on app effectiveness has risen. Furthermore, regulatory processes have awarded market authorisation to at least 25 DTx products, with another 23 commercially available.
Point-of-care testing is the way to go in diagnostics.
To deal with the expected increase in the overall amount of tests in the future in the wake of a probable third wave and its aftermath, self-testing kits, genomic testing, and the introduction of artificial intelligence (AI)-based analytic solutions are being considered. The global point-of-care diagnostics market is divided into product, end-user, prescription mode, and geographic segments. The global point of care diagnostics market was valued at $22,975 million in 2015, and is predicted to increase at a CAGR of 9.4% from 2016 to 2022, to reach $43,336 million.